Catheter-related thrombosis
Conditions
Interventions
experimental group:oral Rivaroxaban 10mg per day for 90 days
blank control:mechanical prophylaxis
Sponsors
LiuZhou People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligibility Criteria: 1. Aged 18-75 years; 2. Patients with malignant tumor who received PICC operation; 3. Ecog0-1 level; 4. Life expectancy > 3 months; 5. Khorana score >= 2 points.
Exclusion criteria
Exclusion criteria: 1. Patients with allergic history to rivaroxaban; 2. Patients with significant or clinically relevant bleeding history in the last 4 weeks; 3. Patients with bleeding risk: thrombocytopenia (platelet count 3 times of the upper limit of normal (ULN) (if liver metastasis occurs, aminotransferase > 5 times of ULN); 6. Patients who need strong cytochrome P450 3A4 (CYP3A4) inducer (rifampin, phenobarbital) or strong CYP3A4 inhibitor (HIV protease inhibitor, ketoconazole); 7. Patients who plan to use bevacizumab or other anticancer drugs known to increase the risk of bleeding; 8. Patients taking anticoagulants for other reasons; 9. Pregnant or nursing women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.occurrence of venous thrombosis;occurrence of a major bleeding event.; | — |
Countries
China
Contacts
Public ContactLiu Ting
Cancer Radiotherapy Department of Liuzhou People's Hospital
Outcome results
None listed